Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Janeiro 2024 - 6:05PM
Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating
genetic medicines for people living with rare and prevalent
diseases, announced that Geoff McDonough, M.D., president and chief
executive officer, will present at the 42nd Annual J.P. Morgan
Healthcare Conference on Wednesday, January 10, 2024 at 3:45 p.m.
PT in San Francisco.
A live webcast of the presentation will be available on the
investor section of the company’s website at
investors.generationbio.com. A replay will be available there for
30 days following the event.
About Generation Bio
Generation Bio is innovating genetic medicines to provide
durable, redosable treatments for people living with rare and
prevalent diseases. The company’s non-viral genetic medicine
platform incorporates novel immune quiet (iqDNA); a unique
cell-targeted lipid nanoparticle (ctLNP) delivery system; and a
highly scalable capsid-free manufacturing process that uses
proprietary cell-free rapid enzymatic synthesis, or RES, to produce
iqDNA. This approach is designed to enable multi-year durability
from a single dose, to deliver large genetic payloads, including
multiple genes, to specific tissues and cell types, and to allow
titration and redosing to adjust or extend expression levels in
each patient. RES has the potential to expand Generation Bio’s
manufacturing scale to hundreds of millions of doses to support its
mission to extend the reach of genetic medicine to more people,
living with more diseases, around the world.
For more information, please visit www.generationbio.com.
Investors and Media ContactMaren
KillackeyGeneration
Biomkillackey@generationbio.com 857-371-4638
Generation Bio (NASDAQ:GBIO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Generation Bio (NASDAQ:GBIO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024